# A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT

> **NCT04488822** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Daiichi Sankyo Co., Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Tenosynovial Giant Cell Tumor

## Interventions

- **DRUG:** Pexidartinib

## Key facts

- **NCT ID:** NCT04488822
- **Lead sponsor:** Daiichi Sankyo Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-25
- **Primary completion:** 2021-10-27
- **Final completion:** 2026-02-28
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04488822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04488822, "A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04488822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*